Patient-derived immunocompetent cultures reveal personalized immunotherapies and new treatment options for therapy resistant patients with high-grade serous ovarian cancer

被引：0
|
作者：
Farkkila, Anniina
Nagaraj, Ashwini S.
Pietila, Elina A.
Salko, Matilda
Erkan, Erdogan P.
Niemiec, Iga
Sirsikar, Aditi
Bao, Jie
Marchi, Giovanni
Nowlan, Kirsten
Hautaniemi, Sampsa
Vaharautio, Anna
Tang, Jing
Haltia, Ulla-Maija
Kekalainen, Eliisa
Virtanen, Anni
Salo, Tuula
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 05期
关键词：
D O I：
10.1158/1538-7445.OVARIAN23-PR-007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PR-007
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Transcriptome analyses reveal new insights on key determinants of perineural invasion in high-grade serous ovarian cancer
    Zheng, Zhen
    Li, Xiao
    Chen, Guoqiang
    Chen, Jing
    Zhu, Xiaolu
    Teng, Yincheng
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
  • [32] Disparities in treatment modalities and survival among older patients with high-grade serous ovarian cancer
    Yan Cai
    Tong Shu
    Hong Zheng
    BMC Women's Health, 24
  • [33] Response to treatment and prognostic significance of supradiaphragmatic disease in patients with high-grade serous ovarian cancer
    Maggiore, U. Leone Roberti
    Bogani, G.
    Martinelli, F.
    Signorelli, M.
    Chiappa, V.
    Lopez, S.
    Granato, V.
    Ditto, A.
    Raspagliesi, F.
    EJSO, 2022, 48 (12): : 2551 - 2557
  • [34] SHOULD AROMATASE INHIBITORS BE USED AS MAINTENANCE TREATMENT IN HIGH-GRADE SEROUS OVARIAN CANCER PATIENTS?
    Heinzelmann-Schwarz, V.
    Knipprath-Meszaros, A. M.
    Francis, J.
    Stadlmann, S.
    Vigo, F.
    Schoetzau, A.
    Singer, G.
    Vetter, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1547 - 1547
  • [35] SHOULD AROMATASE INHIBITORS BE USED AS MAINTENANCE TREATMENT IN HIGH-GRADE SEROUS OVARIAN CANCER PATIENTS?
    Heinzelmann-Schwarz, V.
    Knipprath-Meszaros, A. M.
    Francis, J.
    Stadlmann, S.
    Vigo, F.
    Schoetzau, A.
    Singer, G.
    Vetter, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 307 - 307
  • [36] Disparities in treatment modalities and survival among older patients with high-grade serous ovarian cancer
    Cai, Yan
    Shu, Tong
    Zheng, Hong
    BMC WOMENS HEALTH, 2024, 24 (01)
  • [37] Design of effective combination therapies for high-grade serous ovarian cancer using patient -derived xenograft models
    Iavarone, Claudia
    Zervantonakis, Ioannis
    Chen, Hsing-Yu
    Palakurthi, Sangeetha S.
    Liu, Joyce F.
    Matulonis, Ursula
    Drapkin, Ronny
    Mills, Gordon
    Leverson, Joel
    Sampath, Deepak
    Brugge, Joan
    CANCER RESEARCH, 2016, 76
  • [38] Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status
    Roering, Pia
    Siddiqui, Arafat
    Heuser, Vanina D.
    Potdar, Swapnil
    Mikkonen, Piia
    Oikkonen, Jaana
    Li, Yilin
    Pikkusaari, Sanna
    Wennerberg, Krister
    Hynninen, Johanna
    Grenman, Seija
    Huhtinen, Kaisa
    Auranen, Annika
    Carpen, Olli
    Kaipio, Katja
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [39] Stem cell-like characteristics of patient-derived high-grade serous ovarian cancer xenografts are reversed by miRNA let-7 overexpression
    Chirshev, E.
    Hojo, N.
    Sanderman, L.
    Wang, H.
    Hong, L. J.
    Ioffe, Y. J. M.
    Unternaehrer-Hamm, J.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 178 - 178
  • [40] High-throughput screening of new potential targets for high-grade serous ovarian cancer treatment.
    Dai, Jun
    Erkan, Erdogan Pekcan
    Zhang, Kaiyang
    Kaipio, Katja
    Lamminen, Tarja
    Huhtinen, Kaisa
    Hynninen, Johanna
    Grenman, Seija
    Carpen, Olli Mikael
    Hautaniemi, Sampsa
    Vaharautio, Anna
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 103 - 103
12345